Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring

NCT04375683 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT04375683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring
Lead sponsor
Zhongda Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2020
Completion date
December 30, 2022
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, adult b-cell, bcr-abl1 fusion protein expression